Heart failure reflects impaired cardiac contractility and/or relaxation, resulting from myocardial infarction, hypertension, cardiomyopathy, or valvular disease.
Heart failure reflects impaired cardiac contractility and/or relaxation, resulting from myocardial infarction, hypertension, cardiomyopathy, or valvular disease. Progressive cardiomyocyte death, fibrotic remodelling, and neuroendocrine dysregulation drive the syndrome. Placental mesenchymal stem cells and their exosomes limit adverse remodelling by secreting anti-fibrotic factors (anti-TGF-β signalling), promoting angiogenesis (VEGF, FGF), enhancing cardiomyocyte survival (paracrine anti-apoptotic signals), and modulating inflammatory infiltration (reduced macrophage pro-inflammatory activation). One hundred twenty-four registered clinical trials and twelve actively recruiting sites explore intracoronary or intravenous MSC delivery in post-infarction left-ventricular dysfunction, dilated cardiomyopathy, and advanced heart failure awaiting transplantation.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €18,400–€46,000 (dvcstem.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 124 · 12 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Clinical trial data encompasses phase I–II safety documentation and phase II efficacy assessment across >3,000 treated patients globally. Representative studies report left-ventricular ejection fraction (LVEF) improvements of 5–10 percentage points (e.g., 25% → 35%) in 40–55% of treated cohorts over 6–12 months. Cardiac magnetic resonance imaging shows reduction in scar size and infarct zone wall thickness in responders. Exercise tolerance (6-minute walk distance, VO₂ max) improves modestly in 45–50%. Hospitalisation rates for acute decompensation decline by 25–40% in some cohorts over 12-month follow-up. Mortality benefit remains unproven in phase II; pivotal trials are ongoing.
Depending on assessment, a Heart Failure & Cardiac Repair protocol may draw on:
Heart-failure stem-cell protocols in Sofia and international centres range €6,000–9,000 for treatment courses, typically incorporating 1–2 intracoronary or intravenous MSC infusions, baseline and serial cardiac imaging (echocardiography, cardiac MRI, coronary angiography), biomarker panels (BNP, troponin, inflammatory cytokines), and cardiology supervision. Catheterisation-lab facility fees and interventional cardiology expertise add substantially. Repeat treatment cycles incur cumulative costs; some protocols recommend re-dosing at 6–12 month intervals if functional decline recurs.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Heart Failure & Cardiac Repair cost-by-country breakdown, or compare the best countries for Heart Failure & Cardiac Repair →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Heart Failure & Cardiac Repair.
完整心脏衰竭和心脏修复常见问题 → · 心脏衰竭和心脏修复成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估